Abstract
Recombinant human erythropoietin is arguably the most successful therapeutic application of recombinant DNA technology to date. Since the initial reports — which appeared 22 and 23 years ago1,2 — documented a cure of the anemia of chronic kidney disease with recombinant human erythropoietin, well over a million patients have been treated with it effectively and with minimal drug-related toxicity. Moreover, recombinant human erythropoietin has also been effective in the treatment of patients with cancer, particularly when anemia has been aggravated by chemotherapy. Although recombinant human erythropoietin merits high marks for efficacy and safety, concerns have arisen about two distinct . . .
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
